Literature DB >> 2840834

Pharmacokinetics of pentavalent antimony (Pentostam) in hamsters.

J D Berman1, J F Gallalee, J V Gallalee.   

Abstract

Pentavalent antimony (Sb) is the classical treatment for visceral and cutaneous leishmaniasis. We investigated Sb levels in serum, liver, spleen, and skin of hamsters administered therapeutic dosages of Sb (600 and 300 mg Sb/kg). Single administration of Sb was more effective against hepatic parasites than dividing the same total dose into multiple administrations, which suggests that for elimination of hepatic parasites in vivo, peak Sb concentration is more important than total area-under-the-curve levels. Serum Sb declined with an initial half-life of 1 hr. Skin Sb levels (352 micrograms Sb/g 1 hr after 600 mg Sb/kg) were initially higher than liver levels (77 micrograms Sb/g) or splenic levels (156 micrograms Sb/g), but levels were comparable (7-24 micrograms Sb/g) in the three organs by 8 hr after dosing. The generally comparable levels of Sb in the skin and in the visceral organs support the present clinical practice of administering the same dosage of Sb for cutaneous and visceral leishmaniasis.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2840834     DOI: 10.4269/ajtmh.1988.39.41

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  6 in total

Review 1.  Clinical and experimental advances in treatment of visceral leishmaniasis.

Authors:  H W Murray
Journal:  Antimicrob Agents Chemother       Date:  2001-08       Impact factor: 5.191

2.  Skin uptake, distribution, and elimination of antimony following administration of sodium stibogluconate to patients with cutaneous leishmaniasis.

Authors:  M al Jaser; A el-Yazigi; M Kojan; S L Croft
Journal:  Antimicrob Agents Chemother       Date:  1995-02       Impact factor: 5.191

3.  In vitro antileishmanial properties of tri- and pentavalent antimonial preparations.

Authors:  W L Roberts; J D Berman; P M Rainey
Journal:  Antimicrob Agents Chemother       Date:  1995-06       Impact factor: 5.191

4.  Pharmacokinetics of antimony in patients treated with sodium stibogluconate for cutaneous leishmaniasis.

Authors:  M A Jaser; A el-Yazigi; S L Croft
Journal:  Pharm Res       Date:  1995-01       Impact factor: 4.200

5.  Biodistribution of meglumine antimoniate in healthy and Leishmania (Leishmania) infantum chagasi-infected BALB/c mice.

Authors:  Samanta Etel Treiger Borborema; João Alberto Osso; Heitor Franco de Andrade; Nanci do Nascimento
Journal:  Mem Inst Oswaldo Cruz       Date:  2013-08       Impact factor: 2.743

6.  Pharmacokinetics of neutron-irradiated meglumine antimoniate in Leishmania amazonensis-infected BALB/c mice.

Authors:  Samanta Etel Treiger Borborema; João Alberto Osso; Heitor Franco de Andrade; Nanci do Nascimento
Journal:  J Venom Anim Toxins Incl Trop Dis       Date:  2019-03-11
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.